Abstract
Overview
Introduction
Peripheral artery disease, sometimes also referred to as peripheral vascular
disease, is atherosclerosis in peripheral regions, which can lead to loss of
blood flow to the limbs, and can result in loss of life, limb amputation and
cardiovascular events. The current pharmacological treatment options are
limited, and there are large unmet needs associated with the disease.
Scope
- Evaluate therapies under development for peripheral artery disease (PAD)
- A detailed clinical and commercial assessment of all key emerging therapies
- Epidemiological based sales forecasts for key late-stage developmental
heart failure agents in the seven major markets to 2016
Report Highlights
PAD is severely undertreated and underdiagnosed. Despite the high prevalence
(23.4 million subjects by 2016) and grave consequences, such as cardiovascular
events, amputations and death, PAD is not considered as "fascinating" as
coronary artery disease and the lack of PAD awareness even among physicians is
staggering.
Drug therapy plays a limited role in the management of PAD, due to the
restricted treatment options. For intermittent claudication (IC) patients the
mainstay of pharmacological treatment is prevention of CV events with
antiplatelets and statins. Cilostazol (Pletal), an antiplatelet, is
recommended as first-line therapy for claudication
The new agents in development for PAD are primarily as secondary indications.
This is due to the issues new agents will face reaching the underdiagnosed,
undertreated patient population. Overall, there are very few clinical trials
to develop PAD agents, and the trials are very much underpowered.
Reasons to Purchase
- Understand patient segmentation relevant to pipeline products and analyze
competitive environment at time of product launch
- Justify go/no-go decisions on basis of potential return on investment
- Utilize product profiles to aid pricing and reimbursement decisions
View Cart
